Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Industry Pricing Tactics Are Driving Europe’s Cross-Country Backlash

Norwegian Minister Says Some Drug Prices Are 'Unethical'

Executive Summary

A recent event in Brussels organized by the European Public Health Alliance found that cross-country initiatives on pricing and calls for more R&D and clinical trial transparency are gathering momentum in Europe, but there is still some way to go to address the imbalances in the system. The Pink Sheet spoke to EPHA's Yannis Natsis about the issues raised at the organization's fourth forum on medicines access.

You may also be interested in...



EU Ministers To Debate Pharma ‘Market Failures And High Prices’

Varying levels of access to medicines across the EU are the result of market failures, high prices and pharmaceutical companies’ marketing strategies, says the Council of the EU, which will discuss these issues at the next meeting of European health ministers.

France Backs Disclosure Of Public R&D Funding In Drug Price Negotiations

Civil society groups have welcomed a French parliamentary amendment that would require pharma firms to disclose any public R&D funding when negotiating drug prices with the health authorities. The pharmaceutical industry says the amendment does not take account of the realities of today's business model.

EMA Loses Key Round In Court Battle For Flagship Transparency Policy

The European Medicines Agency may be forced to re-examine whether clinical trial data should be regarded as presumptively confidential under its access to documents policy.

Related Content

Topics

UsernamePublicRestriction

Register

PS141240

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel